圣湘生物科技股份有限公司 关于参加湖南省科创板上市公司 2025 年半年度集体业绩说明会的公告 证券代码：688289 证券简称：圣湘生物 公告编号：2025-057 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、说明会类型 本次投资者说明会以线下参会+视频直播形式召开，公司将针对 2025 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 重要内容提示： 会议召开时间：2025 年 9 月 2 日（星期二）下午 14:00-17:30 会议召开方式：线下参会+视频直播 线下参会地点：湖南省长沙市岳麓区滨江景观道湘江基金小镇 13 栋 5 楼大会 议厅 视频直播平台：上交所"星企航企业信息服务"微信视频号 投资者可于 2025 年 9 月 1 日(星期一)16:00 前通过邮件、电话等形式将需要了 解和关注的问题提前提供给公司。公司将通过本次业绩说明会，在信息披露允许范围 内就投资者普遍关注的问题进行回答。 圣湘生 ...

Group 1 - The core viewpoint of the article is the announcement of a patent application for a reagent composition and kit for cervical cancer detection by Central South University and Shengxiang Biotechnology Co., Ltd [1] - The invention pertains to the field of biological detection technology, specifically focusing on a reagent composition and kit for cervical cancer detection [1] - The reagent composition includes a combination of primers and probes, which are specified by their sequence IDs, indicating a detailed and technical approach to the detection process [1] Group 2 - The disclosed reagent composition demonstrates high sensitivity and specificity in detecting cervical cancer and high-grade cervical precancerous lesions [1]

Group 1 - The core viewpoint of the article highlights the performance of the Science and Technology Innovation Enhanced ETF (588520), which opened with a gain of 0.67% at 1.195 yuan [1] - The top holdings of the ETF include companies such as SMIC, which rose by 1.59%, and Cambricon, which increased by 3.76%, while others like Jianyuan Technology and Transsion Holdings experienced slight declines [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Composite Price Index, managed by Yongying Fund Management Company, with a return of 18.66% since its inception on June 27, 2025, and a return of 13.59% over the past month [1]

Product Registration - The company has received a medical device registration certificate from the National Medical Products Administration for its nucleic acid detection kits for human bocavirus (HBoV) and human metapneumovirus (HMPV) [1] Impact on the Company - HBoV and HMPV are common respiratory viruses that can cause acute respiratory infections, particularly dangerous for children under 5 and the elderly [1] - The symptoms of these infections are similar to those of influenza and other respiratory pathogens, necessitating efficient and accurate detection methods for clinical diagnosis and treatment decisions [1] - The newly certified kits utilize multiplex fluorescent PCR technology, allowing for high sensitivity and specificity in detecting both pathogens [2] - The product enhances the company's existing respiratory infection nucleic acid rapid detection solutions, supporting precise medication for clinical use [2] - The company has over 10 years of experience in the respiratory infectious disease diagnostics field, with a product matrix covering more than 60 items [2] - The new product enriches the company's respiratory pathogen nucleic acid detection offerings and supports a flexible and comprehensive diagnostic solution for various medical institutions [2]

Group 1 - The company, Shengxiang Biology, announced that its products, the nucleic acid test kits for the human bocavirus and human parainfluenza virus (fluorescent PCR method), have recently received the Medical Device Registration Certificate from the National Medical Products Administration [2]

Group 1 - The National authorities are formulating policies to support the development of the marine industry, encouraging participation from state-owned enterprises and private capital [1] - The Shanghai virtual power plant has achieved a record demand response load exceeding 1 million kilowatts for the first time [5] - Several photovoltaic companies have been notified to participate in a discussion meeting organized by relevant departments [3] Group 2 - The Shanghai Stock Exchange is monitoring stocks with significant abnormal fluctuations, including companies like Shangwei New Materials and Dongxin Co., taking regulatory measures [2] - The company Shangwei New Materials announced that its customer TPI Composites, Inc. has filed for bankruptcy protection, which may impact its performance [7] - Shengyi Technology plans to invest approximately 1.9 billion yuan in a smart manufacturing project for high-layer circuit boards [8] Group 3 - Shengyi Electronics reported a revenue of 3.769 billion yuan for the first half of 2025, a year-on-year increase of 91%, with a net profit of 531 million yuan, up 452% [10] - Chip applications from Jingchen Co. are being utilized in robotic arm products by Yushu Technology [9] - The company Sensing Bio has received medical device registration for its nucleic acid testing kits for specific viruses [14] Group 4 - The IPO application of Suzhou Lianxun Instrument Co., Ltd. has been accepted by the Shanghai Stock Exchange, aiming to raise 1.954 billion yuan [15] - Beijing Weiguang Qihang Technology Co., Ltd. has completed an angel round financing of several million yuan for its carbon fiber composite rocket development [16]

证券代码：688289 证券简称：圣湘生物 公告编号：2025-056 人博卡病毒（HBoV）和人偏肺病毒（HMPV）均为近年来备受关注的常见呼吸 道病毒之一，可引起急性呼吸道感染，尤其对 5 岁以下儿童和老年群体构成较大危害。 二者感染症状与流感、腺病毒、合胞病毒等其他呼吸道病原体高度相似，且混合感染 比例居高，临床表现可能从无症状、轻微感冒样症状到支气管炎、肺炎、哮喘急性发 作甚至危及生命，因此，亟需高效精准的检测方法予以快速鉴别，为临床精准诊断与 治疗决策提供循证依据。 公司本次获证的人博卡病毒、人偏肺病毒核酸检测试剂盒，基于多重荧光 PCR 技术，可实现对两种病原体的高灵敏度、高特异性检测，结合公司现有的呼吸道感染 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的产品人博卡病毒、 人偏肺病毒核酸检测试剂盒（荧光 PCR 法）于近日收到由国家药品监督管理局颁发 的《医疗器械注册证》，现将相关情况公告如下： 一、产品注册相关情况 | 注册人名称 | 圣湘生物科 ...

Core Viewpoint - Shengxiang Biotechnology Co., Ltd. is experiencing a decline in stock price while maintaining a competitive position in the medical device industry, with significant growth in revenue and net profit reported in the latest quarterly results [1][2]. Company Overview - Shengxiang Biotechnology focuses on innovative gene technology, providing integrated solutions for in vitro diagnostics, including diagnostic reagents, instruments, and third-party medical testing services [2]. - The company has achieved notable recognition, ranking in the top 100 global medical device companies for two consecutive years and receiving various national and provincial honors [2]. Financial Performance - For Q1 2025, the company reported revenue of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, up 13.22%, with a gross profit margin of 76.71% [2]. Market Position - As of August 14, the company's stock closed at 21.64 yuan, with a rolling PE ratio of 43.79, compared to the industry average of 55.76 and a median of 39.14 [1][3]. - The total market capitalization of Shengxiang Biotechnology is 12.538 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders increased to 20,629, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

通过天眼查大数据分析，圣湘生物科技股份有限公司共对外投资了27家企业，参与招投标项目1057次， 知识产权方面有商标信息387条，专利信息467条，此外企业还拥有行政许可311个。 资金流向方面，今日主力资金净流出2072.15万元，占比成交额10.57%。其中，超大单净流出1542.93万 元、占成交额7.87%，大单净流出529.22万元、占成交额2.7%，中单净流出流出1058.03万元、占成交额 5.4%，小单净流入3130.18万元、占成交额15.96%。 圣湘生物最新一期业绩显示，截至2025一季报，公司营业总收入4.75亿元、同比增长21.62%，归属净利 润9173.55万元，同比增长13.22%，扣非净利润9049.78万元，同比增长22.70%，流动比率4.439、速动比 率4.159、资产负债率23.25%。 天眼查商业履历信息显示，圣湘生物科技股份有限公司，成立于2008年，位于长沙市，是一家以从事医 药制造业为主的企业。企业注册资本57938.8006万人民币，实缴资本12648.8642万人民币。公司法定代 表人为戴立忠。 金融界消息 截至2025年8月11日收盘，圣湘生物（688 ...

Group 1 - The core business of the company is to provide integrated in vitro diagnostic solutions centered on self-innovated gene technology, including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly improved its brand recognition and industry position, receiving high recognition and honors from authoritative institutions both domestically and internationally [2] - The latest performance report for Q1 2025 shows the company achieved an operating income of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, a year-on-year increase of 13.22%, with a gross profit margin of 76.71% [2] Group 2 - As of August 8, the company's stock closed at 21.78 yuan, down 1.94%, with a rolling price-to-earnings (PE) ratio of 44.08 times and a total market value of 12.619 billion yuan [1] - The average PE ratio for the medical device industry is 55.70 times, with a median of 39.08 times, placing the company at the 82nd position in the industry ranking [1][3] - As of Q1 2025, three institutions held shares in the company, with a total of 359,800 shares valued at 0.07 million yuan [1]